Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 August 2016Website:
http://www.protagonist-inc.comNext earnings report:
27 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 13 min agoDividend
Analysts recommendations
Institutional Ownership
PTGX Latest News
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0 A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 37.2% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 1(current)
What type of business is Protagonist Therapeutics?
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
What sector is Protagonist Therapeutics in?
Protagonist Therapeutics is in the Healthcare sector
What industry is Protagonist Therapeutics in?
Protagonist Therapeutics is in the Biotechnology industry
What country is Protagonist Therapeutics from?
Protagonist Therapeutics is headquartered in United States
When did Protagonist Therapeutics go public?
Protagonist Therapeutics initial public offering (IPO) was on 11 August 2016
What is Protagonist Therapeutics website?
https://www.protagonist-inc.com
Is Protagonist Therapeutics in the S&P 500?
No, Protagonist Therapeutics is not included in the S&P 500 index
Is Protagonist Therapeutics in the NASDAQ 100?
No, Protagonist Therapeutics is not included in the NASDAQ 100 index
Is Protagonist Therapeutics in the Dow Jones?
No, Protagonist Therapeutics is not included in the Dow Jones index
When was Protagonist Therapeutics the previous earnings report?
No data
When does Protagonist Therapeutics earnings report?
The next expected earnings date for Protagonist Therapeutics is 27 February 2025